NasdaqGM:NRIXBiotechs
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative?
Nurix Therapeutics announced that CEO Arthur T. Sands will join fireside chats at major upcoming healthcare conferences and that updated efficacy and safety data for its oral BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia will be presented in an oral session at the 2026 European Hematology Association Congress.
The oral presentation slot and conference participation highlight growing scientific and investor attention on Nurix’s targeted protein degradation pipeline,...